Morgan Stanley raised its position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 22.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 174,765 shares of the biopharmaceutical company’s stock after buying an additional 32,276 shares during the period. Morgan Stanley owned 0.17% of Lexicon Pharmaceuticals worth $2,505,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. UBS Group AG raised its stake in shares of Lexicon Pharmaceuticals by 9.3% in the first quarter. UBS Group AG now owns 130,870 shares of the biopharmaceutical company’s stock worth $1,876,000 after buying an additional 11,183 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Lexicon Pharmaceuticals by 1.0% in the first quarter. Geode Capital Management LLC now owns 433,420 shares of the biopharmaceutical company’s stock valued at $6,215,000 after buying an additional 4,141 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Lexicon Pharmaceuticals by 16.3% in the first quarter. Vanguard Group Inc. now owns 4,168,301 shares of the biopharmaceutical company’s stock valued at $59,773,000 after buying an additional 585,222 shares in the last quarter. Loomis Sayles & Co. L P raised its position in shares of Lexicon Pharmaceuticals by 9.0% in the first quarter. Loomis Sayles & Co. L P now owns 913,833 shares of the biopharmaceutical company’s stock valued at $13,104,000 after buying an additional 75,461 shares in the last quarter. Finally, Sector Gamma AS purchased a new position in shares of Lexicon Pharmaceuticals during the first quarter valued at approximately $4,765,000.

Shares of Lexicon Pharmaceuticals, Inc. (LXRX) traded down 1.11% during trading on Friday, reaching $14.25. The company’s stock had a trading volume of 152,014 shares. Lexicon Pharmaceuticals, Inc. has a one year low of $13.41 and a one year high of $19.62. The company has a 50-day moving average price of $15.55 and a 200-day moving average price of $15.43. The stock’s market cap is $1.50 billion.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.45) by $0.12. Lexicon Pharmaceuticals had a negative return on equity of 94.87% and a negative net margin of 170.63%. The business had revenue of $12 million during the quarter, compared to the consensus estimate of $18.34 million. During the same period in the previous year, the business earned ($0.37) EPS. The business’s quarterly revenue was down 40.3% on a year-over-year basis. On average, equities research analysts forecast that Lexicon Pharmaceuticals, Inc. will post ($1.45) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Lexicon Pharmaceuticals, Inc. (LXRX) Shares Bought by Morgan Stanley” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/08/25/lexicon-pharmaceuticals-inc-lxrx-shares-bought-by-morgan-stanley.html.

LXRX has been the subject of several recent research reports. BidaskClub raised Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, June 14th. HC Wainwright set a $27.00 price objective on Lexicon Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, May 3rd. ValuEngine raised Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, June 15th. Cowen and Company reissued a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Tuesday, August 1st. Finally, Zacks Investment Research raised Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, July 18th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $27.00.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

Want to see what other hedge funds are holding LXRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX).

Institutional Ownership by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Stock Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.